Previous 10 | Next 10 |
-Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts expected during 2020- CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMR...
CAMBRIDGE, Mass., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced Phase 1 clinical updates for its Antibody-Coupled T cell Receptor (ACTR) engineered...
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its participation in the following upcoming investor conference: Piper Jaffray...
Unum Therapeutics (NASDAQ: UMRX ): Q3 GAAP EPS of -$0.39 misses by $0.04 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-s...
- Unum’s first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment - - BOXR1030 T cells co-express the GOT2 transgene to improve T ce...
- Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum’s goals are to more selectively target solid tumors with its ACTR platform candidates and improve T cell functionality in the solid tumor microenvironment with its BOXR platform candida...
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance of a presentation at the 34 th annual meeting of the Society for Immuno...
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its participation in the following industry conferences in September: Cell &am...
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced that Charles Wilson, Ph.D., President and Chief Executive Officer, will present at ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...